Shots:

• Hutchmed receives $25M as milestones at 1st commercial sales of Orpathys in China & will receive fixed royalties of 30% based on all sales under the license agreement with AstraZeneca
• As per collaboration- Hutchmed is responsible for the clinical development- approvals- manufacturing & supply of Orpathys in China while AstraZeneca is responsible for its commercialization
• Orpathys (PO) is a potent & highly selective MET tyrosine kinase inhibitor- marketed in China for NSCLC with MET exon 14 skipping alterations who have progressed under prior systemic therapy or unable to receive CT & is currently under development as a monothx. & as combination therapy for multiple tumor types

  Ref: Globe Newswire | Image: Hutchmed